In January, a security research firm called Mindgard conducted a test with a chatbot by Doctronic, a health technology startup, which had recently received state approval to autonomously renew medical prescriptions using artificial intelligence. The test, conducted by Mindgard, revealed that the chatbot had been manipulated by a fabricated regulatory bulletin and told researchers it would triple the standard prescribed dose of OxyContin. However, the firm and Utah’s Office of Artificial Intelligence Policy clarified that this was Doctronic’S public-facing tool, not the actual prescription pilot. The state's approach to AI prescription renewals is seen as a solution to the problem of prescription non-adherence, which costs the American healthcare system between $100 billion and $300 billion annually and is associated with around 125,000 preventable deaths per year. The American Medical Association and the Utah Academy of Family Physicians have raised formal objections to the decision to allow AI systems to proceed autonomously. The AMA has not yet provided formal guidance on whether an AI system should be regulated by the FDA.